Intermediate-size Patient Population Expanded Access Protocol

Inclusion Criteria: * ALS diagnosis * Age 18 -85 years at time of signing informed consent form * Ineligible for other interventional ALS clinical research participation * Vital Capacity greater than 35% of predicted capacity for age, height, and sex * If currently taking standard of care treatment for ALS, must be on stable dose for at least 30 days prior to taking tazbentetol. * Life expectancy of at least 6 months, according to Investigator's judgement Exclusion Criteria: * Clinically significant and/or unstable medical condition (other than ALS) that would pose a risk to the patient * Known ongoing or clinically uncontrolled cardiac disease * Clinically significant liver disease * Clinical significant cognitive impairment or neurological disorder, as determined by Investigator judgement * Concomitant use of another investigational medical product for treatment of ALS * Unable to reliably and regularly swallow whole oral medications on a daily basis